SMARCA4: Current status and future perspectives in non-small-cell lung cancer

被引:38
|
作者
Tian, Yumeng [1 ]
Xu, Lu [1 ]
Li, Xin [1 ]
Li, Heming [1 ,2 ]
Zhao, Mingfang [1 ,2 ]
机构
[1] China Med Univ, Hosp 1, Dept Med Oncol, Shenyang 110001, Peoples R China
[2] China Med Univ, Hosp 1, Dept Med Oncol, 155 Nanjingbei Rd, Shenyang 110001, Liaoning, Peoples R China
关键词
NSCLC; SMARCA4; gene; SMARCA2; SWI/SNF complex; Immunotherapy; CHROMATIN-REMODELING FACTOR; TUMOR-SUPPRESSOR; SYNTHETIC LETHAL; SWI/SNF COMPLEX; CLINICOPATHOLOGICAL CHARACTERISTICS; DOWN-REGULATION; BAF COMPLEXES; DNA-DAMAGE; BRG1; MUTATIONS;
D O I
10.1016/j.canlet.2022.216022
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
SMARCA4, also known as transcription activator, is an ATP-dependent catalytic subunit of SWI/SNF (SWItch/Sucrose NonFermentable) chromatin-remodeling complexes that participates in the regulation of chromatin structure and gene expression by supplying energy. As a tumor suppressor that has aberrant expression in similar to 10% of non-small-cell lung cancers (NSCLCs), SMARCA4 possesses many biological functions, including regulating gene expression, differentiation and transcription. Furthermore, NSCLC patients with SMARCA4 alterations have a weak response to conventional chemotherapy and poor prognosis. Therefore, the mechanisms of SMARCA4 in NSCLC development urgently need to be explored to identify novel biomarkers and precise therapeutic strategies for this subtype. This review systematically describes the biological functions of SMARCA4 and its role in NSCLC development, metastasis, functional epigenetics and potential therapeutic approaches for NSCLCs with SMARCA4 alterations. Additionally, this paper explores the relationship and regulatory mechanisms shared by SMARCA4 and its mutually exclusive catalytic subunit SMARCA2. We aim to provide innovative treatment strategies and improve clinical outcomes for NSCLC patients with SMARCA4 alterations.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives
    C Guven, Deniz
    Sahin, Taha K.
    Dizdar, Omer
    Kilickap, Saadettin
    BIOMARKERS IN MEDICINE, 2020, 14 (14) : 1383 - 1392
  • [2] Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles
    Cho, Ju Hwan
    IMMUNE NETWORK, 2017, 17 (06) : 378 - 391
  • [3] Radiomics in predicting treatment response in non-small-cell lung cancer: current status, challenges and future perspectives
    Madhurima R. Chetan
    Fergus V. Gleeson
    European Radiology, 2021, 31 : 1049 - 1058
  • [4] Radiomics in predicting treatment response in non-small-cell lung cancer: current status, challenges and future perspectives
    Chetan, Madhurima R.
    Gleeson, Fergus V.
    EUROPEAN RADIOLOGY, 2021, 31 (02) : 1049 - 1058
  • [5] Molecular characterization into clinical practice: current status and future perspectives in metastatic non-small-cell lung cancer
    Bonanno, L.
    Calvetti, L.
    Favaretto, A.
    Rosell, R.
    MINERVA BIOTECNOLOGICA, 2011, 23 (04) : 103 - 116
  • [6] Circulating Biomarkers in Non-Small-Cell Lung Cancer: Current Status and Future Challenges
    Matikas, Alexios
    Syrigos, Konstantinos N.
    Agelaki, Sofia
    CLINICAL LUNG CANCER, 2016, 17 (06) : 507 - 516
  • [7] Antivascular agents for non-small-cell lung cancer: current status and future directions
    Amir, Eitan
    Mandoky, Laszlo
    Blackhall, Fiona
    Thatcher, Nick
    Klepetko, Walter
    Ankersmit, Hendrik Jan
    Hoda, Mir Ali Reza
    Ostoros, Gyula
    Dank, Magdolna
    Dome, Balazs
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (11) : 1667 - 1686
  • [8] Current status of immunotherapy for non-small-cell lung cancer
    Imbimbo, Martina
    Lo Russo, Giuseppe
    Blackhall, Fiona
    TUMORI JOURNAL, 2016, 102 (04): : 337 - 351
  • [9] The diverse roles of adiponectin in non-small-cell lung cancer: current data and future perspectives
    Boura, Paraskevi
    Loukides, Stylianos
    Grapsa, Dimitra
    Achimastos, Apostolos
    Syrigos, Konstantinos
    FUTURE ONCOLOGY, 2015, 11 (15) : 2193 - 2203
  • [10] Immune checkpoint inhibitors in non-small-cell lung cancer: current status and future directions
    Yan, Ya-fei
    Zheng, Yong-fa
    Ming, Ping-po
    Deng, Xiao-xi
    Ge, Wei
    Wu, Yao-gui
    BRIEFINGS IN FUNCTIONAL GENOMICS, 2019, 18 (02) : 147 - 156